| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/0269881105059253 © 2005 British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for PsychopharmacologyDivision of Clinical Neurosciences, University of Southampton, Southampton, UK, dsb1{at}soton.ac.uk
Department of Psychiatry, University of Manchester, Manchester, UK
University of Bristol, Bristol, Psychopharmacology Unit, Bristol, UK
Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany
Institute of Psychiatry, Kings College, London, UK
Department of Psychiatry & Behavioral Science, Duke University Medical Center, Durham, USA
School of Behavioral and Cognitive Neurosciences, University Medical Center Groningen, Groningen, the Netherlands
Department of Psychiatry, University of Hertfordshire, Welwyn Garden City, UK
Institute of Psychiatry, Kings College, London, UK
Institute of Psychiatry, Kings College, London, UK
Technical University of Dresden and Max Planck Institute of Psychiatry, Munich, Germany These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.
Key Words: anticonvulsants antidepressants antipsychotics anxiety disorders anxiolytics benzodiazepines cognitive behaviour therapy evidence-based guidelines generalized anxiety disorder obsessive-compulsive disorder panic disorder post-traumatic stress disorder simple phobia social phobia SSRI treatment venlafaxine
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



